<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176865</url>
  </required_header>
  <id_info>
    <org_study_id>MT2002-12</org_study_id>
    <secondary_id>0207M29448</secondary_id>
    <nct_id>NCT00176865</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant for Immunologic or Histiocytic Disorders</brief_title>
  <official_title>Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU),
      anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell
      transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic
      or histiocytic disorders. The researchers hypothesize that this regimen will have a positive
      effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD).

      Patients will be randomized biologically into one of 3 arms based upon donor availability:
      (a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched
      unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched
      unrelated cord blood donors (double cord).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to transplantation, subjects will receive Melphalan, Fludarabine and Anti-Thymocyte
      Globulin (ATG) or Campath. These three drugs are being given to subjects to help the new stem
      cells take and grow. On the day of transplantation, subjects will receive stem cells
      transfused via intravenous (IV) catheter.

      After stem cell transplantation, subjects will be given Cyclosporin A (CsA) and mycophenolate
      mofetil (MMF) to reduce the risk of graft-versus-host disease, the complication that occurs
      when the donor's stem cells react against the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Mixed Chimerism</measure>
    <time_frame>Day 100</time_frame>
    <description>&gt;10% Donor Cells at Day 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 100 Days</measure>
    <time_frame>Day 100</time_frame>
    <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 180 Days</measure>
    <time_frame>Day 180</time_frame>
    <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Donor Chimerism at 365 Days</measure>
    <time_frame>Day 365</time_frame>
    <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 2-4 Acute Graft Versus Host Disease (aGVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3-4 Acute Graft Versus Host Disease (aGVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic Graft Versus Host Disease (cGVHD)</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Chronic graft versus host disease (cGVHD) is a reaction which typically develops 3 to 6 months after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Alive at 100 Days</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Alive at One Year</measure>
    <time_frame>Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Quality of Life (QOL)</measure>
    <time_frame>Pretransplant, 1 year, 2 years and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>X-Linked Lymphoproliferative Disorders</condition>
  <condition>Chediak-Higashi Syndrome</condition>
  <condition>Griscelli Syndrome</condition>
  <condition>Immunologic Deficiency Syndromes</condition>
  <condition>Langerhans-Cell Histiocytosis</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>IV on Day 0</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>hematopoietic stem cell transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m^2 IV Day -7 through Day -3</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 IV Day -1</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin (ATG)</intervention_name>
    <description>30 mg/kg IV Day -5 through Day -1</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>ATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath 1H</intervention_name>
    <description>0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children &lt;40 kg) maintaining a level of &gt;200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin (IVIG)</intervention_name>
    <description>500 mg/kg IV weekly beginning on Day +7 until Day +100</description>
    <arm_group_label>Arm 1 - Matched sibling donor</arm_group_label>
    <arm_group_label>Arm 2 - Matched unrelated donor</arm_group_label>
    <arm_group_label>Arm 3 - Mismatched double cord donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with immunodeficiencies or histiocytic disorders 0-35 years of age with an
        acceptable stem cell donor and disease characteristic defined by the following:

          -  Patients with histocytic disorders (hemophagocytic lymphohistiocytosis of any etiology
             and refractory Langerhans cell histiocytosis) who do not meet eligibility criteria for
             a myeloablative transplant procedure

          -  Patients with immunodeficiency disorders in whom residual immune function may not
             require a fully myeloablative preparative regimen or patient is ineligible for
             standard myeloablative preparative regimen (any form of severe combined
             immunodeficiency [SCID], or other immunodeficiency with T cell defect)

          -  Patients with immunodeficiency disorders that have had poor outcome with myeloablative
             stem cell transplants (including, but not limited to, common variable immunodeficiency
             [CVID], Wiskott Aldrich Syndrome [WAS] if &gt; 5 years of age, ataxia telangiectasia)

          -  Patients with immunodeficiencies or histocytic disorders that require a second stem
             cell transplant (SCT) for any reason

        Exclusion Criteria:

          -  Karnofsky or Lansky performance score &lt;70

          -  Glomerular filtration rate (GFR)&lt;30% predicted

          -  Cardiac function &lt;50% normal by echocardiogram

          -  Serum creatinine &gt; 2x normal for age/weight

          -  Pregnant or lactating females

          -  Active serious infection that has not had an adequate course of therapy pre-SCT. Any
             patient with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC)
             or human immunodeficiency virus (HIV) seropositivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>May 6, 2015</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2017</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cell transplant</keyword>
  <keyword>immunodeficiency</keyword>
  <keyword>donor lymphocyte infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 - Matched Sibling Donor</title>
          <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 - Matched Unrelated Donor</title>
          <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 - Mismatched Double Cord Donors</title>
          <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 - Matched Sibling Donor</title>
          <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 - Matched Unrelated Donor</title>
          <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="B3">
          <title>Arm 3 - Mismatched Double Cord Donors</title>
          <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Mixed Chimerism</title>
        <description>&gt;10% Donor Cells at Day 100</description>
        <time_frame>Day 100</time_frame>
        <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Mixed Chimerism</title>
          <description>&gt;10% Donor Cells at Day 100</description>
          <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 100 Days</title>
        <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
        <time_frame>Day 100</time_frame>
        <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 100 Days</title>
          <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
          <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="6.0"/>
                    <measurement group_id="O2" value="75.5" spread="37.3"/>
                    <measurement group_id="O3" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 180 Days</title>
        <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
        <time_frame>Day 180</time_frame>
        <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 180 Days</title>
          <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
          <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="19.2"/>
                    <measurement group_id="O2" value="73.3" spread="41.7"/>
                    <measurement group_id="O3" value="90.5" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Donor Chimerism at 365 Days</title>
        <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
        <time_frame>Day 365</time_frame>
        <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Donor Chimerism at 365 Days</title>
          <description>The percent of recipient bone marrow and blood cells that are of donor origin.</description>
          <population>Arm 2: 2 of 10 patients not evaluable due to failure to return to clinic for the Day 100 evaluation.
Arm 3: 2 of 6 patients not evaluable due to early death.</population>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" spread="31.4"/>
                    <measurement group_id="O2" value="78.6" spread="38.2"/>
                    <measurement group_id="O3" value="91.7" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 2-4 Acute Graft Versus Host Disease (aGVHD)</title>
        <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 2-4 Acute Graft Versus Host Disease (aGVHD)</title>
          <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3-4 Acute Graft Versus Host Disease (aGVHD)</title>
        <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3-4 Acute Graft Versus Host Disease (aGVHD)</title>
          <description>Acute graft versus host disease (aGVHD) is a reaction occurring within the first 100 days after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs. The severity of aGVHD is graded on a scale of 1 - 4 with the highest number representing the most severe disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic Graft Versus Host Disease (cGVHD)</title>
        <description>Chronic graft versus host disease (cGVHD) is a reaction which typically develops 3 to 6 months after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs.</description>
        <time_frame>6 months and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic Graft Versus Host Disease (cGVHD)</title>
          <description>Chronic graft versus host disease (cGVHD) is a reaction which typically develops 3 to 6 months after transplant where the T- cells of the donor graft attacks the recipient's (host's) skin, GI tract, liver and other organs.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Alive at 100 Days</title>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Alive at 100 Days</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Alive at One Year</title>
        <time_frame>Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Alive at One Year</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Quality of Life (QOL)</title>
        <time_frame>Pretransplant, 1 year, 2 years and 5 years</time_frame>
        <population>PI made decision after IRB approval, but before opening the study to accrual, to not collect QOL data .</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Matched Sibling Donor</title>
            <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Matched Unrelated Donor</title>
            <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - Mismatched Double Cord Donors</title>
            <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
          </group>
        </group_list>
        <measure>
          <title>Compare Quality of Life (QOL)</title>
          <population>PI made decision after IRB approval, but before opening the study to accrual, to not collect QOL data .</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - Matched Sibling Donor</title>
          <description>human leukocyte antigen (HLA) genotypic matched sibling donor
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - Matched Unrelated Donor</title>
          <description>HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor,
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
        <group group_id="E3">
          <title>Arm 3 - Mismatched Double Cord Donors</title>
          <description>two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord).
Stem Cell Transplant: Reduced intensity chemotherapy followed by infusion of hematopoietic stem cells
Fludarabine, melphalan, ATG or Campath: all drugs are given intravenously (IV). Fludarabine x 5 days and melphalan x 1 day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Prolonged QTC interval</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ear drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed growth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syndrome of inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Incipient cataracts, bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Colonic pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemorrhagic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Veno-occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholestasis portal fibrosis and bile duct proliferation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, GI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection, blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection, respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection, skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection, GU</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection, NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Prerenal azotemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intraparenchymal hemorrhage, left frontal lobe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Learning dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ICU dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory distress and apnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin breakdown</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subclavian thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Smith</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

